TABLE 3.

Therapeutic effects of telithromycin and reference compounds on respiratory tract infection caused by erythromycin A-resistant PRSP TUM741^a

Compound	MIC (μg/ml)	Log CFU/lung (mean ± SD)
Control		6.95 ± 0.35
Telithromycin	0.063	1.49 ± 0.32b
Clarithromycin	1	6.46 ± 0.22
Azithromycin	2	6.96 ± 0.60
Cefdinir	2	6.45 ± 0.19
Levofloxacin	2	5.73 ± 1.65c

^aThe compounds, at a dose of 100 mg/kg, were administered orally to five mice twice a day for 3 days. Because the limit of detection was 20 CFU/lung, specimens that were below the limit of detection were recorded as containing 19 CFU/lung. The challenge dose was 7.0 × 10⁵ CFU/mouse. 

^bP < 0.01 represents a statistically significant difference in comparison with the control. 

^cP < 0.05 represents a statistically significant difference in comparison with the control.